Study Title
A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
Study Details
Description:
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment
Sponsor:
Canadian Cancer Trials Group
Contacts:
Wendy Parulekarwparulekar@ctg.queensu.ca
613-533-6430
Government Study Link:
NCT04663997 - Click here to see study onClinicalTrials.gov